Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 2, 2008, Pages 182-185

  Rautemaa, Riina ^a,b   Richardson, Malcolm ^a,b   Pfaller, Michael A ^c   Perheentupa, Jaakko ^d   Saxén, Harri ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Division of Cardiac Anesthesia   (United States)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Amphotericin B; Anidulafungin; APECED; APS I; Candida albicans; Caspofungin; CMC; Fluconazole; Micafungin; Oral candidiasis; Posaconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FINLAND; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYENDOCRINOPATHIES, AUTOIMMUNE; TIME FACTORS;

EID: 51649120783     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.05.007     Document Type: Article

References (11)

1. Carrillo-Muñoz A.J., Quindós G., Ruesga M., Alonso R., del Valle O., Hernández-Molina J.M., McNicholas P., Loebenberg D., and Santos P. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J. Antimicrob. Chemother. 55 (2005) 317-319
2. Jayasinghe M., Schmidt S., Walker B., Röcken M., and Schaller M. Successful treatment of azole-resistant chronic mucocutaneous candidosis with caspofungin. Acta Derm. Venereol. 86 (2006) 563-564
3. Johnson E.M., and Warnock D.W. Azole drug resistance in yeasts. J. Antimicrob. Chemother. 36 (1995) 751-755
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., M27-A2 (2002), National Committee for Clinical Laboratory Standards, Wayne, PA
5. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Clin. Endocrinol. Metab. 91 (2006) 2843-2850
6. Pfaller M.A., and Diekema D.J. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1 (2007) 74-92
7. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekma D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46 (2008) 150-156
8. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., and Diekema D.J. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J. Clin. Microbiol. 46 (2008) 551-559
9. Rautemaa R., Hietanen J., Niissalo S., Pirinen S., and Perheentupa J. Oral and oesophageal squamous cell carcinoma-a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral. Oncol. 43 (2007) 607-613
10. Rautemaa R., Richardson M., Pfaller M.A., Koukila-Kähkölä P., Perheentupa J., and Saxén H. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J. Antimicrob. Chemother. 60 (2007) 889-892
11. Skiest D.J., Vazquez J.A., Anstead G.M., Graybill J.R., Reynes J., Ward D., Hare R., Boparai N., and Isaacs R. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. 44 (2007) 607-614